Stock Events

Stock Events

Enveric Biosciences 

€0
60
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Apr 8
€0.24
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

12NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
-7.41
-5.22
-3.02
-0.83
Expected EPS
-4.5153675
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-8.95MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SLZ.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Corbus Pharmaceuticals
CRBP
Mkt Cap178.43M
Corbus Pharmaceuticals works on developing and commercializing novel therapeutics to treat inflammatory and fibrotic diseases, overlapping with Enveric's target indications.
Aurora Cannabis
ACB
Mkt Cap200.44M
Aurora Cannabis is a major player in the cannabis industry, potentially competing in the medical cannabis space where Enveric operates.
Tilray Brands
TLRY
Mkt Cap807.33M
Tilray is a global leader in cannabis research, cultivation, processing, and distribution, potentially overlapping with Enveric's market in cannabinoid-based therapeutics.
Canopy Growth
CGC
Mkt Cap501.04M
Canopy Growth Corporation operates in the cannabis and hemp business, directly competing in the broader market for cannabinoid-based products.

About

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Show more...
CEO
Dr. Joseph Edward Tucker Ph.D.
Employees
7
Country
United States
ISIN
US29405E4061
WKN
000A41091

Listings

STU
DE
SLZ0.STU
MU
DE
SLZ0.MU
F
DE
SLZ0.F
XNAS
US
ENVB

0 Comments

Share your thoughts

FAQ

What is Enveric Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Enveric Biosciences stocks are traded under the ticker SLZ.F.
What is Enveric Biosciences revenue for the last year?▼
Enveric Biosciences revenue for the last year amounts to 0 EUR.
What is Enveric Biosciences net income for the last year?▼
SLZ.F net income for the last year is -8.95M EUR.
Does Enveric Biosciences pay dividends?▼
Yes, SLZ.F dividends are paid en. The last dividend per share was 0.24 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Enveric Biosciences have?▼
As of April 29, 2026, the company has 7 employees.
In which sector is Enveric Biosciences located?▼
Enveric Biosciences operates in the Health & Wellness sector.
When did Enveric Biosciences complete a stock split?▼
The last stock split for Enveric Biosciences was on October 28, 2025 with a ratio of 1:12.
Where is Enveric Biosciences headquartered?▼
Enveric Biosciences is headquartered in Naples, United States.